Eribulin plus trastuzumab in pretreated HER2-positive advanced breast cancer patients: safety and efficacy. An Italian experience

BACKGROUND: Chemotherapy plus targeted therapy is the established treatment for human epidermal growth factor receptor 2 (HER2)–overexpressing breast cancer (BC). Limited data regarding the safety and activity of the combination of eribulin and trastuzumab (E/T) in pretreated HER2-positive advanced...

Descripción completa

Detalles Bibliográficos
Autores principales: Lutrino, Eufemia S., Orlando, Laura, Febbraro, Antonio, Giampaglia, Marianna, Zamagni, Claudio, Schiavone, Paola, Scavelli, Claudio, Dima, Gianluca, Fedele, Palma, Giordano, Guido, Bilancia, Domenico, Quaranta, Anna Maria, Rubino, Daniela, Filippelli, Gianfranco, Fontanella, Caterina, Caliolo, Chiara, Marino, Antonella, Calvani, Nicola, Ferrara, Pasqualinda, Cinieri, Saverio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2019
Materias:
Original Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7372580/
https://www.ncbi.nlm.nih.gov/pubmed/31847742
http://dx.doi.org/10.1177/0300891619887225

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7372580/
https://www.ncbi.nlm.nih.gov/pubmed/31847742
http://dx.doi.org/10.1177/0300891619887225

Ejemplares similares